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ABBREVIATIONS 
IRCH    immune checkpoint inhibitor-related cholangiohepatitis 
ICIs    Immune checkpoint inhibitors 
irAE    Immune-related adverse event 
CTLA-4                         Cytotoxic T lymphocyte-associated antigen 4 
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PD-(L)1   Anti-programmed-death-1/programmed-death-ligand-1 
AIH                                         Autoimmune hepatitis 
TCZ                                     Tocilizumab  
CRP                                     C-reactive protein 
CS                                     Corticosteroid 
MMF                                     Mycophenolate mofetil 
IL-1RA                          Interleukin-1 receptor antagonists 
IFN-α/β   Interferon-α/β 
PDN    Prednisone 
TNF-α    Tumor necrosis factor-α 
IL    Interleukin 
IL-1RA    Interleukin-1 receptor antagonist 
IFN    Interferon 
TNF     Tumor necrosis factor 
CCL    C-C motif chemokine ligand 
CXCL    C-X-C motif chemokine ligand 
MCP-1    Monocyte chemoattractant protein-1 
MP    Intravenous methylprednisolone 
MIP     Macrophage inflammatory protein 
KC     Keratinocyte chemoattractant 
MIG     Monokine-induced by gamma interferon 
SDF-1     Stromal cell-derived factor 1 
BLC     B lymphocyte chemoattractant 
NGF     Nerve growth factor 
BDNF    Brain-derived neurotrophic factor 
EGF     Epidermal growth factor 
FGF-2     Fibroblast growth factor 2 
HGF    Hepatocyte growth factor 
LIF    Leukemia inhibitory factor 
PDGF-BB    Platelet-derived growth factor-BB 
PlGF-1    Placental growth factor-1 
SCF    Stem cell factor 
VEGF    Vascular endothelial growth factor 
BAFF     B-cell activating factor 
GM-CSF   Granulocyte-macrophage colony-stimulating factor 
G-CSF    Granulocyte colony-stimulating factor 
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ABSTRACT 
Introduction. For patients with corticosteroid (CS)-refractory immune checkpoint inhibitor-
related cholangiohepatitis (irCH), no consensus exists regarding treatment, and outcomes 
remain poor. We evaluated the possibility of personalized treatment according to the patient’s 
cytokine profile and the immunohistopathologically assessment of the predominant immune 
infiltrate type of liver tissue. 
Methods. NSCLCs with CS-refractory irCH were analyzed by immunohistochemistry (IHC) 
of liver biopsy, serum cytokine panel, and CyTOF assessment of PBMC immune cell 
monitoring. 
Results.  A total of three consecutives patients with irCH were identified. We found a 
predominant T-cell infiltrate and an IFN-γ/Th1 proinflammatory cytokine profile. Here, we 
report for the first time that a T-cell-targeted therapy with the IL-6 receptor-neutralizing 
antibody tocilizumab (TCZ), which inhibits signaling downstream of interferon-γ (IFN-γ) and 
several other JAK-dependent cytokines, is an effective single cytokine-directed therapy for 
CS-refractory irCH. Three patients with severe and CS-refractory irCH who were treated 
with TCZ showed persistent clinical and biological remission. 
Conclusion. Dysregulation of the IL-6/T-cell axis may contribute to the pathogenesis of CS-
refractory irCH. Our observations suggest that IL-6 blockade appears to show promise in the 
treatment of CS-refractory irCH. The results from our three patients need to be confirmed in a 
larger patient population.  
 
 
INTRODUCTION 
Immune-mediated hepatotoxicity associated with immune checkpoint inhibitors (ICIs) is a 
well-recognized potentially serious immune-related adverse event (irAE), with a wide clinical 
spectrum ranging from asymptomatic elevations in liver enzymes detected during routine 
monitoring, as seen in 25% of patients with grade 3-4 hepatitis1, to acute liver failure, which 
is a major cause of death.2-4 Fever, abdominal pain and jaundice in cases of cholestatic injury 
have also been described.1 Few cases of fulminant hepatic failure have been reported.4,5 Risk 
depends on the class of ICIs, dosage and eventual comedications.1,6,7 Severe hepatitis (grade 
3 and 4) has been reported in approximately 1 – 2.2% of patients treated with nivolumab or 
pembrolizumab monotherapy.8,9 
Jo
urn
al 
Pr
e-p
roo
f
4 
 
First-line treatment with high doses of systemic corticosteroids (CSs) is usually 
recommended for persistent grade 2 and grade 3-4 liver injuries.10,11 Unfortunately, limited 
data are available on the efficacy of second-line therapies. Currently, there are no specific 
therapeutic guidelines for CS-refractory irCH management, and the majority of patients are 
treated with various sequences of immunosuppressant drugs. This paucity of large-scale 
randomized controlled trials in this field makes the treatment of CS-refractory irCH very 
challenging. 
Although the pathogenesis of irCH is not fully understood, we investigated the possibility of 
treating severe irCH according to the cytokine profile and on the basis of an 
immunohistopathologically guided strategy.3 Given the presence of a predominant T-cell 
immune infiltrate on the immunohistopathological liver assessment and of the IFN-γ/TH1/IL-
6-cytokine signature, blocking IL-6 signaling represents an attractive target.12-14 IL-6 is an 
upstream pleotropic proinflammatory cytokine produced during the early stages of 
inflammation and plays a central role in driving the pathogenesis of autoimmune hepatitis15, 
as well as in the proliferation, survival and activation of cytotoxic T cells.16 Furthermore, the 
IL-17/IL-6 axis plays an important role in the pathogenesis of many liver diseases by 
regulating innate immunity, adaptive immunity, and autoimmunity.15 
Here, we report, for the first time, three consecutive patients with severe irCH who received 
successful personalized treatment with the anti-IL6R antibody tocilizumab (TCZ) based on 
their cytokine profiles and on the liver biopsy predominant immune infiltrate, resulting in 
rapid clinical and biological remission. We performed molecular and cellular characterization 
of each patient’s response by longitudinal profiling of the cytokine and chemokine serum 
levels using a 50-marker panel and analyzing liver biopsies. 
 
METHODS 
Clinical Data. We report three consecutive patients with non-small cell lung cancer who 
developed cholangiohepatitis while undergoing pembrolizumab treatment. The clinical and 
biological characteristics of the patients as well as the therapy regimens are summarized in 
Table 1. 
 
RESULTS 
Clinical course with tocilizumab treatment in CS-refractory irCH. The baseline Th1 
cytokine profile showed high IL-6 levels (patient 1), and predominant T-cell infiltrate was 
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visible in the livers of the three patients (Figure 2). Thus, TCZ, an anti-IL6R antibody, was 
administered to all three patients, resulting in rapid improvement of their clinical status. 
Similarly, rapid improvements in liver function indicators including aspartate transaminase 
(AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and bilirubin, as well as 
ferritin, were observed (Figure 1). Of note, the adjunction of TCZ allowed normalization of 
creatinine (patient 1) and hemoglobin (patient 2). Patients 1 and 2 required two doses of TCZ, 
whereas patient 3 required only one dose. 
 
Serum cytokine signature associated with CS-refractory irCH. Despite the previous 
course of CS, withdrawn 10 days before performing the first cytokine panel, patient 1 
exhibited high baseline levels of circulating proinflammatory cytokines, including IFN-γ and 
IFN-γ-induced chemokines (IL-6, IL-18, CXCL1, CXCL9, CXCL10, CXCL11, CXCL13 and 
G-CSF). We also observed elevated levels of anti-inflammatory cytokines, such as IL-10 and 
IL-1 receptor antagonist (IL-1RA). The level of TNF-α was not increased (Figure 2A). For 
patients 2 and 3, although the cytokine panel evaluation was performed six days after starting 
high-dose CS, which most likely affected the results, we observed an increase in pro-
inflammatory cytokines including IFN-γ-induced chemokines (IL-18, IL-7, CXCL1, CXCL9, 
CXCL10 and CXCL13), as well as IL-10 anti-inflammatory cytokines (Table 1). After two 
administrations of TCZ, the levels of proinflammatory cytokines, especially IFN-γ- and IFN-
γ-induced chemokines, were significantly decreased for patient 1 (Figure 2). As expected and 
reported previously, the serum level of IL-6 increased during TCZ treatment.17 
 
Histologic and immunohistochemical testing. The diagnosis of cholangiohepatitis was 
supported by histopathological findings of the liver biopsies in the three patients. In patient 1, 
acute hepatitis with portal inflammation, interface hepatitis and lobular microgranulomatous 
inflammation was found together with focal cholangitis. Immunostaining revealed that 
inflammatory cells were mainly T lymphocytes, almost equally CD4+ and CD8+, and that 
plasma cells were exceptional (Figure 2B). Transjugular liver biopsy performed in patient 2 
demonstrated a background of steatofibrosis related to previous known alcohol consumption, 
with a superimposed acute inflammatory process. Severe portal inflammation with interface 
hepatitis was associated with ductular reaction and biliary metaplasia of the periportal 
hepatocytes. Again, inflammation mainly comprised T lymphocytes, with CD4+ and CD8+ 
cells in almost equal proportions (Figure 2C). At approximately day 20, despite the repeated 
administration of high intravenous methylprednisolone (MP) over several days, the patient’s 
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liver function tests and ferritin have not been significantly improved, requiring a high dose of 
MP. The liver biopsy was then repeated for patient 2 after two weeks. Histopathologic 
findings in the second biopsy were consistent with evolving immunotherapy-related 
cholangitis. The amount of inflammation had decreased, but the bile duct lesions were more 
important, associated with ductopenia, biliary infarcts and histological signs of chronic 
cholestasis (Figure 2C, second biopsy). Within the residual inflammatory infiltrate, T 
lymphocytes still predominated, and CD4+ and CD8+ cells were still equally represented. In 
patient 3, portal inflammation was again composed mainly of T lymphocytes, with CD4+ and 
CD8+ cells organized around the portal bile duct in a concentric way reminiscent of primary 
biliary cholangitis or primary sclerosing cholangitis, and infiltrating the epithelial lining of 
the duct (Figure 2D). There was also some interface and lobular hepatitis. 
 
 
DISCUSSION 
Poor outcomes have been reported in patients presenting with CS-refractory irCH. Little 
progress in the development of new treatments has been made in recent decades. Additional 
antiproliferative immunosuppressants are recommended in refractory cases. Given the 
paucity of data on second-line immunosuppressive therapy in irCH, recommendations are 
defined by analogy with autoimmune hepatitis, indicating mycophenolate mofetil and 
tacrolimus as potentially effective therapeutic agents.11 Antithymocyte globulin has also been 
reported as an effective treatment.18 
 
Given this lack of established therapies, we investigated the possibility of personalized 
treatment for CS-refractory irCH according to the patient’s cytokine profile and to the 
immunohistopathologically personalized assessment of liver tissue. Targeted therapies aim to 
inhibit key proinflammatory proteins involved in the pathophysiological processes of irCH, 
allowing better efficiency and fewer potential side effects of the high immunosuppressive 
burden. 
 
This pathogenic cytokine signature is characterized by strong IFN-γ/Th1 cell polarization 
(Figure 2A and table 1). Of note, our patients also showed elevated levels of anti-
inflammatory regulatory cytokines such as IL-1RA and IL-10 (Figure 2A and table 1). 
Presumably, these antagonist pathways are induced to contain the inflammatory response by 
suppressing the hyperactivation of Th1 cell and monocyte/macrophage functions and to 
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protect the host from an excessive immune response. Interestingly, we found markedly 
increased serum levels of CXCL9 and CXCL10, chemokines induced by IFNγ. Increased 
levels of these CXCL3 ligands are apparent in primary biliary cirrhosis and autoimmune 
hepatitis. CXCL9 correlates with liver inflammation and fibrosis19, whereas CXCL10 is 
known to be upregulated in patients affected by nonalcoholic steatohepatitis (NASH)20. These 
ligands activate the NF-κB pathway and pro-inflammatory cytokines such as TNF-α, IL-1β, 
and MCP-121, acting as a promoter of both innate and adaptative inflammatory responses. 
Further investigations are required to validate CXCL9 and CXCL10 as biological markers of 
liver inflammatory injury in irCH. 
 
An interesting feature of CS-refractory irCH was the predominant T-cell infiltration 
composed equally of CD4+ and CD8+ cells on liver biopsy in the three patients, despite 
several days of high-dose CS (Figure 2). The second liver biopsy for patient 2 remained rich 
in T lymphocytes, suggesting a possible link between liver function degradation and the 
presence of T lymphocytes resistant to high doses of CS. Common histopathologic findings 
in irCH include panlobular hepatitis and isolated central zonal necrosis. In severe cases, pan- 
or multiacinar confluent necrosis can be observed.7 Microabscesses and granulomatous or 
microgranulomatous lesions are also seen.1,22 Portal inflammation targeting the bile duct with 
ductular reaction and cholangitis are characteristic of the biliary pattern.22 Compared to 
histopathologic findings seen in autoimmune hepatitis (AIH), plasmacytosis, hepatocellular 
rosettes and confluent necrosis are less frequent in ICI-induced liver disease, while lobular 
hepatitis and portal inflammation are common to both entities.7 Immunostaining typically 
demonstrates T-lymphocyte-predominant infiltrates. Infiltration of predominantly CD8+ 
lymphocytes is observed in patients receiving anti-CTLA-4, while CD8+ and CD4+ cells are 
equally represented in liver injury induced by anti-PD1/PD-L1.1 The importance of CD8+ 
cell infiltration is also different from that in classical autoimmune hepatitis and cholangitis.22 
 
Unfortunately, although the histopathologic assessment would be helpful to support the 
diagnosis, to evaluate the degree of tissue injury and to individualize the treatment strategy, 
liver biopsy is not routinely performed. 
 
IL-6 is an upstream pleotropic proinflammatory cytokine that plays a central role in driving 
the pathogenesis of autoimmune hepatitis15 along with the proliferation, survival and 
activation of cytotoxic T cells.16 Furthermore, the IL-17/IL-6 axis plays an important role in 
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the pathogenesis of many liver diseases by regulating innate immunity, adaptive immunity, 
and autoimmunity.15 Therefore, in contrast to blocking single cytokines further downstream, 
which might not have any impact on the activity of the various other cytokines propagating 
immune activation and end-organ damage, blocking the IL-6/IL-6R axis affects the 
production of multiple cytokines that contribute to liver injury. Patient 1 serum analysis 
revealed high levels of IL-6 and IL-18, which are proinflammatory cytokines, both reported 
to be involved in the pathogenesis of autoimmune hepatitis. Suppressing this pathological 
immune activation with the anti-IL-6R antibody TCZ seems to be a promising strategy for 
CS-refractory irCH, resulting in rapid resolution of symptoms and normalization of the 
pathological laboratory values. 
 
Of note, IL-6 promotes the production of JAK-STAT–dependent cytokines (e.g., interferon-γ 
and Th1 cytokines), differentiation of IL-17-producing T helper cells (Th17), and 
proliferation and cytotoxic activation of CD8+ T cells while inhibiting the expression of 
regulatory T cells (Tregs).23 The imbalance resulting from IL-6 hypersignaling potentially 
increases this inflammatory response initiated by activated T lymphocytes in patients 
developing irAEs as reported in supplementary figure 1 where, despite the use of MP for 
several days, PBMC T cells of patient 3 exhibited elevated levels of CD38 and HLA-DR 
markers which are characteristic of high level immune activation. Very interestingly, in 
contrast to MP, TCZ treatment allowed the normalization of T cell phenotypic profiles.  
 
Most interestingly, it was reported that the increase in hepatic IL-6 expression contributes to 
the pathogenesis of AIH.15 Furthermore, in patients receiving anti-PD(L)1, Treg depletion 
may result from inhibition of PD1-mediated enhancement of Foxp3.24 
 
Additionally, the emerging role of IL‐6 hypersignaling in the impairment of the immune 
response against tumors has been recognized. Dysfunction of innate and adaptive immunity 
mediated by IL-6 results in reduced activation and priming of tumor‐specific T cells, 
decreased Th1 differentiation of CD4+ T cells, inhibited maturation of dendritic cells, and 
increased production of immune‐suppressive factors such as IL‐10, prostaglandin E2 (PGE 
2), and vascular endothelial growth factor (VEGF).25 Therefore, given their potential 
antitumorigenic properties, IL-6 blocking therapeutic agents, such as TCZ, represent an 
interesting option for the management of CS-refractory irAEs. Such an antitumor synergy 
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could be evoked in patients 1 and 2, whose cancers remained in partial remission despite the 
absence of oncological treatment for 7-8 months. 
 
Although less frequently than other immunosuppressive drugs (ISs), such as mycophenolate 
mofetil or azathioprine, elevations in liver enzyme levels and extremely rare cases of severe 
drug-induced liver injury have been reported with TCZ, making TCZ a relatively safe IS. 
 
Taken together, the data regarding the rapid and sustained clinical and biological response to 
TCZ treatment suggest that dysregulation of the IL-6/T-cell axis contributes to the 
pathogenesis of CS-refractory irCH. The results from our patients need to be confirmed in a 
larger patient population, yet our observations suggest that IL-6 blockade appears to show 
promise in the treatment of irCH. We point to the urgent need for additional studies to 
improve insights into the molecular and cellular mechanisms underlying irCH to draw more 
patient- and histological-tailored guidelines for management. 
 
 
Figure legends 
Table 1. Characteristics, clinical, biochemical data, and treatment regimen of the three 
patients. ANA, antinuclear antibody; AIH, autoimmune hepatitis; AIN, acute interstitial 
nephritis; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline 
phosphatase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; irAEs, immune-
related adverse events; CS, corticosteroid; TCZ, tocilizumab; PR, partial remission. 
 
Figure 1. Assessment of clinical and biochemical remission of irCH with tocilizumab 
therapy. The three panels show biochemical data at diagnosis, during treatment and at 
discharge. Despite receiving high-dose MP boluses, the two patients had an immune flare 
associated with rapid increases in ferritin, AST, ALT, bilirubin, and creatinine levels and 
decreases in hemoglobin levels. Patients 1 and 2 received two doses of TCZ 8 mg/kg and 
patient 3 received only one dose. This allowed for the rapid decrease in liver function tests 
and ferritin levels and was associated with the rapid improvement in hemoglobin levels and 
clinical amelioration. The patients were then progressively weaned from CSs and did not 
experience any recurrence. NSAID, Nonsteroidal anti-inflammatory drug; IV, intravenous, 
CS; corticosteroid; TCZ, tocilizumab.  
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Figure 2. Assessment of cytokine signatures and histological characteristics. Panel A 
shows the results of the cytokine panel of PBMCs. Heat map of scaled pg/µl values. Columns 
(i.e., cytokines) are scaled to facilitate the comparison of the detected levels of the cytokines, 
which are color-coded from white to red (low to high levels of cytokines detected). The panel 
was obtained for patient 1 at diagnosis and repeated after TCZ treatment. Panels B-F show 
the results of histological features and immunohistochemical testing of liver biopsy 
specimens from patient 1 (B), patient 2 (C) and patient 3 (D). Figure 2B-Case 1. Portal 
inflammation with interface hepatitis and focal cholangitis (arrows). Inflammation was 
composed of T lymphocytes, with CD4+ and CD8+ cells almost equally represented. Figure 
2C-case 2. First biopsy. Portal inflammation with interface hepatitis, ductular reaction and 
biliary metaplasia on cytokeratin 7 (K7) immunostaining. Inflammatory infiltrate was 
composed of T lymphocytes, with CD4+ and CD8+ cells almost equally represented. Figure 
2C-case 2. Second biopsy. Bile duct alterations and vacuolization (arrows). Bile infarcts 
(arrow) and biliary metaplasia on K7 immunostaining together with ductopenia. Figure 2D-
case 3. Inflammation is mainly organized around the bile duct in a concentric way better seen 
on K7 immunostaining. Inflammatory infiltrate is made of T lymphocytes, with both CD4+ 
and CD8+ cells. 
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Table 1. Patient’s characteristics with clinical and biochemical data at diagnosis and during treatment 
 Patient 1  Patient 2  Patient 3  
Gender Male Male Female  
Age 83 years 67 years 70 years 
Disease Squamous cell carcinoma stage IIIB Squamous cell carcinoma stage IIIB Lung adenocarcinoma stage IVB 
Cancer treatment Carboplatin, vinorelbin, pembrolizumab (4 
cycles)    
Carboplatin, gemcitabine, pembrolizumab (4 
cycles) 
Pembrolizumab (1 cycle) 
Additional work-up AST 874 U/L (14-50) 
ALT 655 U/L (11-50) 
ALP  969 U/L (36-108) 
Gamma-GT 1736 U/L (10-71) 
Bilirubin 54 µmol/L (0-21) 
Ferritin 13095 µg/L (30-400) 
CRP 45 mg/L (<10) 
ESR >44 mm/h (<10) 
 
Infectious panel negative for:  
HAV, HBV, HCV, HEV, CMV, HIV 1/2, HSV 
1/2, TB spot 
 
EBV DNA (quantitative PCR) whole blood : 
4787 copies/ml  
EBV DNA (quantitative PCR) liver biopsy : 
negative 
 
Auto-immune panel negative for:  
Complement (C3c, C4), ANA and autoantibodies 
associated with autoimmune liver diseases (anti-
smooth muscle, anti-actin, anti-M2, anti-gp210, 
anti-sp100, anti-LKM1, anti-LC1, anti-SLA) 
 
Cytokine and chemokine panel:  
Increasing of:   
• Pro-inflammatory cytokines: IFN-γ, IL-
6, IL-18, CXCL1, CXCL9, CXCL10, 
CXCL11, CXCL13, G-CSF 
• Anti-Inflammatory cytokines: IL-1RA, 
IL-10 
    
Liver biopsy: cholangio-hepatitis 
Acute hepatitis with portal inflammation and 
interface hepatitis, together with focal cholangitis 
and lobular microgranulomatous reaction. 
Inflammation mainly composed of T 
AST 184 U/L (14-50) 
ALT 331 U/L (11-50) 
ALP  1018 U/L (36-108) 
Gamma-GT 3475 U/L (10-71) 
Bilirubin 178 µmol/L (0-21) 
Ferritin 1350 µg/L (30-400) 
CRP 106 mg/L (<10) 
ESR >110 mm/h (<10) 
 
Infectious panel negative for:  
HAV, HBV, HCV, HEV, CMV, EBV, VZV, 
HIV 1/2, TB spot 
 
Auto-immune panel negative for:  
Complement (C3c, C4), ANA and 
autoantibodies associated with autoimmune 
liver diseases (anti-smooth muscle, anti-actin, 
anti-M2, anti-gp210, anti-sp100, anti-LKM1, 
anti-LC1, anti-SLA) 
 
Cytokine and chemokine panel (performed 6 
days after starting high-dose CS that probably 
affected results):  
Increasing of:  
• Pro-inflammatory cytokines: IFN-γ-
induced chemokines such as CXCL1, 
CXCL9 and CXCL10 
• Anti-Inflammatory cytokines: IL-10 
 
 
First liver biopsy: cholangio-hepatitis 
Severe mixed portal inflammation with interface 
hepatitis, ductular reaction and biliary 
metaplasia of periportal hepatocytes. 
Inflammation mainly composed of T 
lymphocytes, with CD4+ and CD8+ equally 
represented. Background of alcohol-related 
AST 531 U/L (14-50) 
ALT 1037 U/L (11-50) 
ALP  636 U/L (36-108) 
Gamma-GT 1617 U/L (10-71) 
Bilirubin 40 µmol/L (0-21) 
Ferritin 3506 µg/L (30-400) 
CRP 17 mg/L (<10) 
 
Infectious panel negative for:  
HAV, HBV, HCV, HEV, CMV, EBV, VZV, 
HIV 1/2, TB spot 
 
Auto-immune panel negative for:  
Complement (C3c, C4), ANA and 
autoantibodies associated with autoimmune 
liver diseases (anti-smooth muscle, anti-
actin, anti-M2, anti-gp210, anti-sp100, anti-
LKM1, anti-LC1, anti-SLA) 
 
Cytokine and chemokine panel (performed 5 
days after starting high-dose CS that 
probably affected results):  
Increasing of:  
• Pro-inflammatory cytokines: IL-7, 
IL-18 and IFN-γ-induced 
chemokines such as (CXCL9, 
CXCL13 and HGF) 
 
 
Liver biopsy: hepato-cholangitis 
Portal inflammation with some interface 
hepatitis but mostly with a concentric 
peribiliary tropism, mainly composed of T 
lymphocytes, with CD4+ and CD8+ almost 
equally represented.  
 
Jo
urn
al 
Pr
e-p
roo
f
lymphocytes, with CD4+ and CD8+ almost 
equally represented. Absence of fibrosis.  
 
steatofibrosis. 
Second liver biopsy after 2 weeks of CS at day 
20: predominant cholangitis lesional pattern 
with altered bile ducts, ductopenia, biliary 
infarcts. Inflammation mainly composed of T 
lymphocytes, with CD4+ and CD8+ equally 
represented.  
 
Imaging features PET-CT: no liver metastasis, regression of the 
mediastinal lymph nodes and shrinkage of the 
lung mass in the left upper lobe 
Abdominal MRI: hepatomegaly and intrahepatic 
biliary dilatations with enhancement, without 
choledocal lesion or enlargement. 
Abdominal MRI: absence of organomegaly, 
absence of intra or extrahepatic biliary 
dilatations 
Concurrent irAEs AIN (AKIN stage II)   
Time point of 
diagnosis of irCH 
After 4 cycles  
(70 days after starting treatment, 36 days after 
last dose)  
 
After 4 cycles 
(123 days after starting treatment, 63 days after 
last dose) 
After 1 cycle  
( 30 days after starting the first dose) 
Type and duration of 
CS therapy  
Methylprednisolone: 125 mg/day for 3 days, 500 
mg/day for 2 days than 0.5 mg/kg/day for 14 
days, than oral prednisone 0.5 mg/kg/day with 
rapid tapering 
14 days to reach ≤ 20 mg of CS per day since the 
first TCZ 
Methylprednisolone started at 62.5-125 mg/day 
for 11 days than oral prednisone 1 mg/kg/day 
with rapid tapering  
11 day to reach ≤ 20 mg of CS per day since the 
first TCZ 
Methylprednisolone started at 125 mg/day 
for 5 days, than stop for 2 days, than 125 
mg/day for 5 days, than oral prednisone 1 
mg/kg for 5 days, than rapid tapering  
 
11^3 day to reach ≤ 0.5 mg/kg of CS per day 
since TCZ 
Additional treatment TCZ 8 mg/kg iv 
2 doses 
TCZ 8 mg/kg iv 
2 doses 
TCZ 8 mg/kg iv 
1 dose  
Cancer response  PR  PR   
 
 
 
ANA antinuclear Antibody 
AIH autoimmune hepatitis 
AIN acute interstitial nephritis 
ALT alanine transaminase 
AST aspartate transaminase 
ALP Alkaline Phosphatase 
CRP C-reactive protein 
ESR erythrocyte sedimentation rate 
irAEs immune-related adverse events 
IMH immune-mediated hepatitis 
CS corticosteroids 
TCZ tocilizumab 
PR partial remission 
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Day
Cycle 1 
Pembrolizumab
MP iv 125 mg 3d, than 250 mg 1d, 
than 125 mg 4d and 62.5 2d
TCZ iv 
480 mg
Oral PDN 
50 mg/d
Oral PDN 
45 mg/d
Oral PDN 
35 mg/d
-16 d 0 10 20 30 40
Cycle 4 
carboplatin,
gemcitabine,
pembrolizumab
1st liver 
biopsy
MP iv started 
at 125 mg/d
2nd liver
biopsy
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TCZ iv 
500 mg
TCZ iv 
500 mg
25
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pembrolizumab
liver 
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MP iv 125 mg 3d
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than 0.5 mg/kg/d for 14d
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TCZ iv 
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